Editorial
Nitroso–Redox Balance in the Cardiovascular System
N Engl J Med 2004; 351:2112-2114November 11, 2004
- Article
In this issue of the Journal, Taylor and colleagues report the results of the African-American Heart Failure Trial (A-HeFT), a double-blind, randomized trial that evaluated the effect of the addition of isosorbide dinitrate and hydralazine to the best conventional therapy in patients with symptomatic congestive heart failure who identified themselves as black.1 The results with the combination therapy were markedly positive, meeting the composite end point of the trial, which included death from any cause, a first hospitalization for heart failure, and quality-of-life measures. In addition, there was an impressive reduction in the rate of death from any cause of approximately 45 percent, leading to an early termination of the study.
This trial raises fascinating issues regarding heart-failure therapeutics and variations in drug susceptibility among populations. Attempting to understand these issues requires insight into the pharmacologic and biologic underpinnings of any drug combination that may enhance nitric oxide availability. This regimen of isosorbide dinitrate and hydralazine (which are available individually as inexpensive, generic formulations), initially selected for its vasodilatory properties in the Veterans Administration Heart Failure Trials (V-Heft) I and II,2 turns out to be one of the most fortuitous combination therapies in cardiovascular medicine. Isosorbide dinitrate is an organic nitrate that stimulates nitric oxide signaling,3 and hydralazine is a vasodilator and antioxidant that inhibits the enzymatic formation of reactive oxygen species such as superoxide (O2 ) by NADH and NADPH oxidases.4 The success of this therapy now brings to the forefront the need to understand the underlying biochemistry of nitric oxide and superoxide and their interaction, since these molecules are key determinants of cellular redox balance.
Nitric oxide and superoxide are physiologically produced, reactive molecules with unpaired electrons (i.e., free radicals). Nitric oxide is a ubiquitous signaling molecule that influences organ function by means of post-translational modification of effector molecules; this occurs most often at cysteine residues and is termed S-nitrosylation.5 S-nitrosylation is a highly versatile signaling mechanism that affects hundreds of biologic events in a tightly regulated and reversible manner.5 Superoxide plays a key role in this regulation by facilitating S-nitrosylation of proteins when it is present at physiologic levels but disrupting this signaling mechanism when it is present at elevated levels.6 Specifically, superoxide reacts with the same cysteine thiol moieties on proteins that are regulated by S-nitrosylation, preventing this reaction from occurring7 (Figure 1Figure 1
Consequences of Disrupting the Balance between Nitric Oxide and Superoxide Production in the Cardiovascular System of Patients with Congestive Heart Failure.). Excess superoxide also reacts directly with nitric oxide, disrupting its physiologic signaling and potentially leading to the production of other toxic and reactive molecules, notably peroxynitrite.8 Thus, a central pathophysiological consequence of oxidative stress is the disruption of nitric oxide signaling, and it is therefore appropriate to think of cellular redox balance in terms of the nitroso–redox balance. From this perspective, the administration of a combination of a nitric oxide stimulator and an antioxidant turns out to be an excellent choice and one that addresses fundamental biochemical derangements in the failing cardiovascular system (Figure 1).S-nitrosylation regulates key processes in both the heart and the vascular tree, and thus, a nitroso–redox imbalance can affect both cardiac performance and vascular tone. In the heart, S-nitrosylation of ion channels maintains the calcium cycle within heart-muscle cells responsible for normal systolic and diastolic function.9 In conductance vessels (those of medium-to-large size), nitric oxide acts as the prototypical endothelium-derived relaxing factor by activating guanylyl cyclase to produce cyclic guanosine monophosphate. Finally, in the microcirculation, nitric oxide carried by S-nitrosohemoglobin regulates blood flow. It is important to note that nitric oxide is not produced by endothelial cells in the microcirculation but, rather, is carried there by hemoglobin itself.10 In an elegant series of experiments carried out by Jonathan Stamler's group and recently confirmed by other laboratories,11 red cells were shown to regulate the arteriolar microcirculation, coupling oxygen delivery with blood flow.10
A disruption in nitroso–redox signaling clearly has the potential to contribute to congestive heart failure. At an enzymatic level, oxidant-producing enzymes are up-regulated12 and the level or spatial location of nitric oxide–producing enzymes — nitric oxide synthases — are altered within cells.13 In addition, a deficiency of nitric oxide synthase may actually increase the activity of oxidases, since nitric oxide may be a physiologic down-regulator of superoxide production.6 The levels of specific vascular NADPH oxidases are increased in the failing circulatory system, at least partly in response to increased levels of angiotensin II, suggesting a link between neurohormonal activation and a nitroso–redox imbalance.14 In addition, the levels and activity of xanthine oxidase, an oxidase (for which NADH and oxygen are electron acceptors) produced in the liver, gut, and heart that circulates in the blood, are increased throughout the cardiovascular system, contributing to vasoconstriction and depressed cardiac function.8,12,15
With regard to the arteriolar vascular bed, the site that determines vascular resistance and therefore stress on the heart, Datta and colleagues recently demonstrated that the delivery of S-nitrosohemoglobin is impaired in the presence of both heart failure and one of the major risk factors for heart failure, diabetes.11 Disruption of nitric oxide delivery to the microcirculation almost certainly contributes to the vasoconstriction and uncoupling of oxygen delivery in skeletal muscle that are characteristic of heart failure. Thus, although the sources of oxidative stress may differ and several different enzymatic and biochemical mechanisms can disrupt nitric oxide signaling, a central problem in the failing circulation appears to be a shift in the nitroso–redox balance away from physiologic S-nitrosylation to one of oxidative stress.
In addition to diminished nitric oxide production, alterations in the levels of nitric oxide synthases may also contribute directly to oxidative stress in patients with heart failure by producing superoxide when nitric oxide synthase cofactors are deficient. Finally, in some circumstances such as acute ischemia, sepsis, or heart failure, the production of nitric oxide synthase is abnormally elevated, usually as a result of the induction of a high-output isoform (inducible nitric oxide synthase), leading to an adverse situation of nitrosative stress.9 Cellular damage in this situation is often potentiated because the stimuli that lead to the formation of inducible nitric oxide synthase are also capable of up-regulating oxidases, and concomitant elevations in nitric oxide and superoxide lead to the formation of peroxynitrite.8
Insight into this pathophysiological signaling is highly relevant to therapeutics. Impairment in cardiac-energy use in patients with heart failure is reversible with the short-term use of xanthine oxidase inhibitors.12 A prolonged nitroso–redox imbalance leads to the consequences more traditionally ascribed to oxidative stress — cell damage as a result of the oxidation of nucleic acids and proteins, cell loss owing to apoptosis, and phenotypic alteration as a result of the activation of abnormal gene programs (the fetal gene program and resultant cardiac hypertrophy are a prime example of this phenomenon).8 The results of the A-HeFT strongly suggest that a regimen with the potential to restore the nitroso–redox balance probably also affects cardiac remodeling.
Viewed from the nitroso–redox perspective, it seems logical that the combination of isosorbide dinitrate and hydralazine should have potent cardiovascular effects in the failing circulation. Interestingly, although these are old drugs, the specific mechanism of action for these compounds has been identified only in the past decade. Munzel et al. demonstrated that hydralazine inhibits membrane-bound enzymatic sources of superoxide that use NADH and NADPH as electron acceptors4; the specific oxidase involved remains to be identified. Whether organic nitrates are themselves nitric oxide donors or require enzymatic biotransformation remains a matter of controversy. Recently, the metabolism of organic nitrates by mitochondrial aldehyde oxidase has been found to have a role in activating the vasodilatory nitric oxide pathway.3 Ironically, it is this enzyme that not only induces nitric oxide bioactivity but also leads to nitrate tolerance, a circumstance in which superoxide is generated, thereby providing insight into the mechanism by which hydralazine may offset this phenomenon.4
Indeed, the success of the A-HeFT coupled with the growing understanding of the biochemistry of nitric oxide and superoxide sets the stage for investigations to determine the precise mechanism of action of this drug combination and, just as important, could lead to many other novel therapies aimed at restoring the nitroso–redox balance. To the extent that this therapy ultimately proves to work preferentially in certain demographic subgroups, knowledge of the operative biochemical pathways will facilitate the search for the genetic and environmental determinants of this selective susceptibility.
Supported by a grant (HL-065455) from the National Institutes of Health.
Source Information
From the Department of Medicine, Cardiology Division, Johns Hopkins University School of Medicine, Baltimore.
- References
References
1
Taylor AL ,Ziesche S ,Yancy C , et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-2057
Full Text | Web of Science | Medline2
Cohn JN ,Johnson G ,Ziesche S , et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310
Full Text | Web of Science | Medline3
Sydow K ,Daiber A ,Oelze M , et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 2004;113:482-489
Web of Science | Medline4
Munzel T ,Kurz S ,Rajagopalan S , et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase: a new action for an old drug. J Clin Invest 1996;98:1465-1470
CrossRef | Web of Science | Medline5
Stamler JS ,Lamas S ,Fang FC . Nitrosylation: the prototypic redox-based signaling mechanism. Cell 2001;106:675-683
CrossRef | Web of Science | Medline6
Khan S, Lee KH, Minhas KM, et al. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc Natl Acad Sci U S A (in press).
7
Xu L ,Eu JP ,Meissner G ,Stamler JS . Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science 1998;279:234-237
CrossRef | Web of Science | Medline8
Berry CE ,Hare JM . Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 2004;555:589-606
CrossRef | Web of Science | Medline9
Hare JM . Nitric oxide and excitation-contraction coupling. J Mol Cell Cardiol 2003;35:719-729
CrossRef | Web of Science | Medline10
Singel DJ ,Stamler JS . Blood traffic control. Nature 2004;430:297-297
CrossRef | Web of Science | Medline11
Datta B ,Tufnell-Barrett T ,Bleasdale RA , et al. Red blood cell nitric oxide as an endocrine vasoregulator: a potential role in congestive heart failure. Circulation 2004;109:1339-1342
CrossRef | Web of Science | Medline12
Cappola TP ,Kass DA ,Nelson GS , et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001;104:2407-2411
CrossRef | Web of Science | Medline13
Damy T ,Ratajczak P ,Shah AM , et al. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 2004;363:1365-1367
CrossRef | Web of Science | Medline14
Mollnau H ,Wendt M ,Szocs K , et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric Oxide/cGMP signaling. Circ Res 2002;90:E58-65
CrossRef | Web of Science | Medline15
Landmesser U ,Spiekermann S ,Dikalov S , et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002;106:3073-3078
CrossRef | Web of Science | Medline
- Citing Articles (28)
Citing Articles
1
Maria F Garcia-Saura, Fumito Saijo, Nathan S Bryan, Selena Bauer, Juan Rodriguez, Martin Feelisch. (2012) Nitroso-Redox Status and Vascular Function in Marginal and Severe Ascorbate Deficiency. Antioxidants & Redox Signaling120205064514003
CrossRef2
Mehnaz Khan, Jochen Steppan, Karl Schuleri, Sungwoo Ryoo, Eric Tuday, Lukasz Bugaj, Lakshmi Santhanam, Tal Berkowitz, Daniel Nyhan, Artin A. Shoukas, Dan E. Berkowitz. (2011) Upregulation of arginase-II contributes to decreased age-related myocardial contractile reserve. European Journal of Applied Physiology
CrossRef3
Michael Andrades, Arian Morina, Snežana Spasić, Ivan Spasojević. (2011) Bench-to-bedside review: Sepsis - from the redox point of view. Critical Care 15:5, 230
CrossRef4
Yuliy Y. Chirkov, Michele Sciscio, Aaron L. Sverdlov, Sue Leslie, Peter R. Sage, John D. Horowitz. (2010) Hydralazine does not Ameliorate Nitric Oxide Resistance in Chronic Heart Failure. Cardiovascular Drugs and Therapy 24:2, 131-137
CrossRef5
Barry H. Trachtenberg, Joshua M. Hare. (2009) Biomarkers of Oxidative Stress in Heart Failure. Heart Failure Clinics 5:4, 561-577
CrossRef6
Essam H. Mattar, Al-Said A. Haffor. (2009) Effect of Dobutamine and Hyperoxia on Free Radicals Production in Relation to the Ultrastructural Alterations in the Endothelial of Myocardial Capillary in Rats, Rattus norvigicus. Ultrastructural Pathology 33:5, 209-215
CrossRef7
Claudia Penna, Daniele Mancardi, Raffaella Rastaldo, Pasquale Pagliaro. (2009) Cardioprotection: A radical view. Biochimica et Biophysica Acta (BBA) - Bioenergetics 1787:7, 781-793
CrossRef8
M. J. Thomson, M. P. Frenneaux, J. C. Kaski. (2009) Antioxidant treatment for heart failure: friend or foe?. QJM 102:5, 305-310
CrossRef9
Dennis M. McNamara, S. William Tam, Michael L. Sabolinski, Page Tobelmann, Karen Janosko, Lakshmi Venkitachalam, Elizabeth Ofili, Clyde Yancy, Arthur M. Feldman, Jalal K Ghali, Anne L. Taylor, Jay N. Cohn, Manuel Worcel. (2009) Endothelial Nitric Oxide Synthase (NOS3) Polymorphisms in African Americans With Heart Failure: Results From the A-HeFT Trial. Journal of Cardiac Failure 15:3, 191-198
CrossRef10
Pawan D. Patel, Jose L. Velazquez, Rohit R. Arora. (2009) Endothelial dysfunction in African-Americans. International Journal of Cardiology 132:2, 157-172
CrossRef11
Tao Li, Jing Li, Jin Liu, Pu Zhang, Wei Wu, Ronghua Zhou, Guohua Li, Wensheng Zhang, Mingliang Yi, Han Huang. (2009) Polymerized placenta hemoglobin attenuates ischemia/reperfusion injury and restores the nitroso-redox balance in isolated rat heart. Free Radical Biology and Medicine 46:3, 397-405
CrossRef12
Jordi Vilaro, Roberto Rabinovich, Jose Manuel Gonzalez-deSuso, Thierry Troosters, Diego Rodríguez, Joan Albert Barberà, Josep Roca. (2009) Clinical Assessment of Peripheral Muscle Function in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Physical Medicine & Rehabilitation 88:1, 39-46
CrossRef13
Clyde W. Yancy. (2008) Race-based therapeutics. Current Hypertension Reports 10:4, 276-285
CrossRef14
Yan Lin, Li-Na Wang, Yu-Hui Xi, Hong-Zhu Li, Feng-Gang Xiao, Ya-Jun Zhao, Ye Tian, Bao-Feng Yang, Chang-Qing Xu. (2008) l-Arginine Inhibits Isoproterenol-Induced Cardiac Hypertrophy through Nitric Oxide and Polyamine Pathways. Basic & Clinical Pharmacology & Toxicology 103:2, 124-130
CrossRef15
RICHARD W. TROUGHTON, JAY RITZEMA-CARTER, M. GARY NICHOLLS. 2008. Role of Neurohormones. , 345-366.
CrossRef16
Oberdan Parodi, Renata De Maria, Elena Roubina. (2007) Redox state, oxidative stress and endothelial dysfunction in heart failure: the puzzle of nitrate–thiol interaction. Journal of Cardiovascular Medicine 8:10, 765-774
CrossRef17
Sung Jung Hong, Giridharan Gokulrangan, Christian Schöneich. (2007) Proteomic analysis of age dependent nitration of rat cardiac proteins by solution isoelectric focusing coupled to nanoHPLC tandem mass spectrometry. Experimental Gerontology 42:7, 639-651
CrossRef18
Clyde W. Yancy. (2007) Race-based therapeutics. Current Cardiovascular Risk Reports 1:2, 108-117
CrossRef19
Roberto M. Saraiva, Khalid M. Minhas, Meizi Zheng, Eleanor Pitz, Adriana Treuer, Daniel Gonzalez, Karl H. Schuleri, Koenraad M. Vandegaer, Lili A. Barouch, Joshua M. Hare. (2007) Reduced neuronal nitric oxide synthase expression contributes to cardiac oxidative stress and nitroso-redox imbalance in ob/ob mice. Nitric Oxide 16:3, 331-338
CrossRef20
Melinda S. Carmody, Joe R. Anderson. (2007) BiDil (Isosorbide Dinitrate and Hydralazine). Cardiology in Review 15:1, 46-53
CrossRef21
S William Tam, Michael L Sabolinski, Manuel Worcel, Milton Packer, Jay N Cohn. (2007) Lack of Bioequivalence between Different Formulations of Isosorbide??Dinitrate and Hydralazine and??the??Fixed-Dose Combination of??Isosorbide Dinitrate/Hydralazine. Clinical Pharmacokinetics 46:10, 885-895
CrossRef22
Joseph A Franciosa. (2006) Fixed combination isosorbide dinitrate–hydralazine for nitric-oxide-enhancing therapy in heart failure. Expert Opinion on Pharmacotherapy 7:18, 2521-2531
CrossRef23
Melvin R Echols, Clyde W Yancy. (2006) Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure. Vascular Health and Risk Management 2:4, 423-431
CrossRef24
Johannes-Peter Stasch, Peter M. Schmidt, Pavel I. Nedvetsky, Tatiana Y. Nedvetskaya, Arun Kumar H.S., Sabine Meurer, Martin Deile, Ashraf Taye, Andreas Knorr, Harald Lapp, Helmut Müller, Yagmur Turgay, Christiane Rothkegel, Adrian Tersteegen, Barbara Kemp-Harper, Werner Müller-Esterl, Harald H.H.W. Schmidt. (2006) Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. Journal of Clinical Investigation 116:9, 2552-2561
CrossRef25
Éva Katona, Georgios Settakis, Zsuzsa Varga, György Paragh, Dániel Bereczki, Béla Fülesdi, Dénes Páll. (2006) Target-organ damage in adolescent hypertension. Analysis of potential influencing factors, especially nitric oxide and endothelin-1. Journal of the Neurological Sciences 247:2, 138-143
CrossRef26
Roberto M Saraiva, Joshua M Hare. (2006) Nitric oxide signaling in the cardiovascular system: implications for heart failure. Current Opinion in Cardiology 21:3, 221-228
CrossRef27
PATRICIA O'MALLEY. (2005) Ethnic Pharmacology. Clinical Nurse Specialist 19:6, 291-293
CrossRef28
Frank J. Giordano. (2005) Oxygen, oxidative stress, hypoxia, and heart failure. Journal of Clinical Investigation 115:3, 500-508
CrossRef
